Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22231169
Woo CW, Kutzler L, Kimball SR, Tabas I (2012) Toll-like receptor activation suppresses ER stress factor CHOP and translation inhibition through activation of eIF2B. Nat Cell Biol 14, 192-200 22231169
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S540-p - eIF2B-epsilon (human)
Modsite: MDsEEPDsRGGsPQM SwissProt Entrez-Gene
Orthologous residues
eIF2B‑epsilon (human): S540‑p, eIF2B‑epsilon (mouse): S536‑p, eIF2B‑epsilon (rat): S535‑p, eIF2B‑epsilon (rabbit): S540‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  kidney, liver, macrophage, MEF (fibroblast)
Cellular systems studied:  cell lines, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme

S544-p - eIF2B-epsilon (human)
Modsite: EPDsRGGsPQMDDIK SwissProt Entrez-Gene
Orthologous residues
eIF2B‑epsilon (human): S544‑p, eIF2B‑epsilon (mouse): S540‑p, eIF2B‑epsilon (rat): S539‑p, eIF2B‑epsilon (rabbit): S544‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  kidney, liver, macrophage, MEF (fibroblast)
Cellular systems studied:  cell lines, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme

Y307-p - PPP2CA (human)
Modsite: VTRRtPDyFl_____ SwissProt Entrez-Gene
Orthologous residues
PPP2CA (human): Y307‑p, PPP2CA iso2 (human): Y253‑p, PPP2CA (mouse): Y307‑p, PPP2CA (rat): Y307‑p, PPP2CA (pig): Y307‑p, PPP2CA (cow): Y307‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  kidney, liver, macrophage, MEF (fibroblast)
Cellular systems studied:  cell lines, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS decrease
phosphorylated peptide LPS inhibit treatment-induced decrease
PP1, tunicamycin decrease
SU6656, tunicamycin decrease
Downstream Regulation
Effect of modification (function):  activity, inhibited
Effect of modification (process):  signaling pathway regulation, translation, inhibited

S535-p - eIF2B-epsilon (rat)
Modsite: VDPEELDsRAGsPQL SwissProt Entrez-Gene
Orthologous residues
eIF2B‑epsilon (human): S540‑p, eIF2B‑epsilon (mouse): S536‑p, eIF2B‑epsilon (rat): S535‑p, eIF2B‑epsilon (rabbit): S540‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  kidney, liver, macrophage, MEF (fibroblast)
Cellular systems studied:  cell lines, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS decrease
tunicamycin LPS augment treatment-induced decrease
TICAM1 (human) decrease
Downstream Regulation
Effect of modification (function):  activity, inhibited, enzymatic activity, induced
Effect of modification (process):  signaling pathway regulation, translation, inhibited
Comments:  CHOP activity induced